ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$65.43 USD
+1.50 (2.35%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $65.50 +0.07 (0.11%) 7:14 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ANIP 65.43 +1.50(2.35%)
Will ANIP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIP
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
Other News for ANIP
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 ...
ANIP Faces Setback in Legal Dispute Over Royalties
ANI Pharmaceuticals: Classic Case Of Capital Intensive Growth Hampering Value
Optimistic Growth Potential for ANI Pharmaceuticals Despite Challenges in DME Treatment
ANI Pharmaceuticals (ANIP) Shares Drop Following Clinical Trial Results